MarginsXMarginsX
Home › Markets › Health Care › CRON

Cronos Group Inc. Common Share (CRON)

CRON trades on Nasdaq in Health Care, Medicinal Chemicals and Botanical Products . Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$3.27
-3.25% on the day
Market cap
$1.2B
Small cap
Revenue · 2025
$146.6M
+24.6% on 2024
Net income · 2025
-$9.4M
-6.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1656472/000165647226000016/0001656472-26-000016-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerCRON on Nasdaq
SectorHealth Care
Industry Medicinal Chemicals and Botanical Products
CountryCanada
IPO yearNot reported by the screener
SEC CIK0001656472
SEC industry codeMedicinal Chemicals & Botanical Products
Incorporated inBC
Canadian listingTSX: CRON

Financials · 2025

LineValue
Revenue$146.6M
Net income-$9.4M
Operating income-$17.4M
Net margin-6.4%
Operating margin-11.9%
Revenue growth+24.6%
Cash$791.8M
Total assets$1.2B
P/E (computed)Net income was not positive
P/S (computed)8.2×

Warning signs

Cash runway
Cash-flow positive
$411.2M cash at September 30, 2026
Share count, 1 year
-4.3%
2025-11-03 to 2026-11-02 · -3.8% over 3 years
Going-concern doubt
No
10-Q filed November 5, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.10-Q 2026-11-05
Cash and burn$411.2M cash; operating cash flow $20.3M a quarter.Report 2026-09-30
Shares outstanding366,471,299 (2026-11-02); 382,893,267 a year earlier; 381,113,564 three years earlier.Cover page 2026-11-02
Reverse splits, 3 yearsNone foundNone on EDGAR
Shelf and offerings, 12 months0 S-3/F-3 shelf filings; 0 424B5 takedownsNone on EDGAR
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorDavidson & Company LLP, Vancouver, CanadaPCAOB Form AP 2026-03-09
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Quarterly results

QuarterRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
Q3 2026
2026-09-30
$63.5M$13.8M$34.3M$411.2MNo debt tags$206.2M10-Q 2026-11-05
Q2 2026
2026-06-30
$53.0M$32.1M$24.0M$467.0MNo debt tags$179.1M10-Q 2026-08-06
Q1 2026
2026-03-31
$45.2M$13.8M$10.9M$821.9MNo debt tags$159.5M10-Q 2026-05-11
Q4 2025
2025-12-31
$44.5M-$1.8M$11.8M$791.8MNo debt tags$146.6M10-K 2026-02-26
Q3 2025
2025-09-30
$36.3M$26.0M$13.3M$784.2MNo debt tags$132.4M10-Q 2026-11-05
Q2 2025
2025-06-30
$33.5M-$39.7M$2.8M$794.4MNo debt tags$130.3M10-Q 2026-08-06
Q1 2025
2025-03-31
$32.3M$6.1M-$2.1M$797.8MNo debt tags$124.6M10-Q 2026-05-11
Q4 2024
2024-12-31
$30.3M$43.7M$7.7M$858.8MNo debt tags$117.6M10-K 2026-02-26

From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest annual report10-K2026-02-26
Latest quarterly / interim10-Q2026-11-05
Latest current report8-K2026-11-05
Latest proxyDEFA14A2026-04-24

Source: SEC EDGAR submissions feed, 502 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week-6.4%
1 month+5.6%
3 months+7.0%
Year to date+28.5%
1 year+36.3%
From 52-week high-9.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Medicinal Chemicals and Botanical Products

TickerCompanyPriceDayMarket cap
RLXRLX Technology Inc.$1.53-1.92%$1.9B
TRLVTrulieve Cannabis Corp. Subordinate Voting Shares$10.33-5.23%$2.0B
RGCRegencell Bioscience Holdings Limited$4.72-4.45%$2.3B
OBIOOrchestra BioMed Holdings Inc.$7.12-1.79%$560.4M
DFTXDefinium Therapeutics Inc. Common Shares$30.16-5.99%$4.1B
TLRYTilray Brands Inc. Common Stock$2.34-3.70%$345.8M
SNDLSNDL Inc. Common Shares$1.34-2.19%$326.0M
ACBAurora Cannabis Inc. Common Shares$4.61-6.68%$303.1M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier